NASDAQ:MXCT MaxCyte Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.83 -0.42 (-8.00%) (As of 06/29/2022 03:59 PM ET) Add Compare Share Today's Range$4.77▼$5.2050-Day Range$3.59▼$5.8452-Week Range$3.36▼$17.44Volume32,044 shsAverage Volume623,912 shsMarket Capitalization$490.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MXCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address MXCT Stock Forecast (MarketRank)Overall MarketRank™0.33 out of 5 starsMedical Sector1340th out of 1,432 stocksCommercial Physical Research Industry21st out of 24 stocksAnalyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for MaxCyte. Previous Next 0.0 Community Rank Outperform VotesMaxCyte has received 0 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMaxCyte has received 0 “underperform” votes. (Add your “underperform” vote.)MarketBeat's community ratings are surveys of what our community members think about MaxCyte and other stocks. Vote “Outperform” if you believe MXCT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MXCT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMaxCyte does not currently pay a dividend.Dividend GrowthMaxCyte does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MaxCyte insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.11% of the stock of MaxCyte is held by insiders.Percentage Held by Institutions65.86% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MaxCyte are expected to decrease in the coming year, from ($0.28) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MaxCyte is -28.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MaxCyte is -28.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaxCyte has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MaxCyte (NASDAQ:MXCT)MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Read More MXCT Stock News HeadlinesJune 23, 2022 | finance.yahoo.comWe Think MaxCyte (LON:MXCT) Can Afford To Drive Business GrowthJune 22, 2022 | americanbankingnews.comCritical Analysis: MaxCyte (NASDAQ:MXCT) versus National Research (NASDAQ:NRC)June 13, 2022 | americanbankingnews.comMaxCyte (MXCT) vs. Its Peers Head to Head SurveyJune 10, 2022 | americanbankingnews.comMaxCyte (MXCT) vs. The Competition Head to Head SurveyJune 10, 2022 | americanbankingnews.comHead to Head Survey: MaxCyte (NASDAQ:MXCT) and Medpace (NASDAQ:MEDP)June 8, 2022 | americanbankingnews.comHead-To-Head Survey: MaxCyte (MXCT) vs. The CompetitionJune 7, 2022 | americanbankingnews.comHead-To-Head Contrast: MaxCyte (MXCT) versus Its CompetitorsJune 7, 2022 | americanbankingnews.comHead-To-Head Review: MaxCyte (MXCT) versus Its RivalsJune 6, 2022 | msn.comLooking Into MaxCyte's Return On Capital EmployedJune 5, 2022 | americanbankingnews.comMaxCyte (MXCT) and Its Rivals Critical ReviewJune 5, 2022 | americanbankingnews.comContrasting MaxCyte (MXCT) & The CompetitionJune 5, 2022 | americanbankingnews.comMaxCyte (MXCT) and Its Peers Head to Head AnalysisJune 4, 2022 | americanbankingnews.comAnalyzing MaxCyte (MXCT) & Its PeersSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MXCT CUSIPN/A CIK1287098 Webmaxcyte.com Phone301 944 1700Fax301-944-1703Employees84Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today6/29/2022Next Earnings (Estimated)9/12/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($0.170010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19.08 million Net Margins-41.15% Pretax Margin-41.15% Return on Equity-7.39% Return on Assets-6.78% Debt Debt-to-Equity RatioN/A Current Ratio17.09 Quick Ratio16.67 Sales & Book Value Annual Sales$33.89 million Price / Sales14.47 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book1.85Miscellaneous Outstanding Shares101,540,000Free Float96,351,000Market Cap$490.44 million OptionableOptionable BetaN/A MaxCyte Frequently Asked Questions Should I buy or sell MaxCyte stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MaxCyte stock. View analyst ratings for MaxCyte or view top-rated stocks. How has MaxCyte's stock performed in 2022? MaxCyte's stock was trading at $6.43 at the start of the year. Since then, MXCT shares have decreased by 24.9% and is now trading at $4.83. View the best growth stocks for 2022 here. When is MaxCyte's next earnings date? MaxCyte is scheduled to release its next quarterly earnings announcement on Monday, September 12th 2022. View our earnings forecast for MaxCyte. How were MaxCyte's earnings last quarter? MaxCyte, Inc. (NASDAQ:MXCT) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The company earned $11.59 million during the quarter, compared to the consensus estimate of $11 million. MaxCyte had a negative net margin of 41.15% and a negative trailing twelve-month return on equity of 7.39%. View MaxCyte's earnings history. What guidance has MaxCyte issued on next quarter's earnings? MaxCyte issued an update on its first quarter 2022 earnings guidance on Tuesday, April, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11 M-, compared to the consensus revenue estimate of $8.46 million. Who are MaxCyte's key executives? MaxCyte's management team includes the following people: Mr. Douglas Arthur Doerfler, Founder, Pres, CEO & Exec. Director (Age 66, Pay $1.39M)Mr. Ronald Evan Holtz CPA, Ph.D., Chief Financial Officer (Age 64, Pay $649.38k)Dr. J. Stark Thompson Ph.D., Consultant (Age 80, Pay $84.71k)Dr. Cenk Sumen, Chief Scientific Officer (Age 49)Mr. Sean Menarguez, Director of Investor RelationsMr. Maher Masoud, Exec. VP, Gen. Counsel & Sec. (Age 47)Mr. Thomas Michael Ross, Exec. VP of Global Sales (Age 61)Mr. Kevin Gutshall, VP of Strategy & Corp. Devel.Dr. James Brady Ph.D., Sr. VP of Technical Applications & Customer SupportDr. Sarah Haecker Meeks Ph.D., Sr. VP of Bus. Devel. Who are some of MaxCyte's key competitors? Some companies that are related to MaxCyte include National Research (NRC), SomaLogic (SLGC), Absci (ABSI), Avista Public Acquisition Corp. II (AHPA), Inotiv (NOTV), Science 37 (SNCE), Starpharma (SPHRY), Luna Innovations (LUNA), Zymergen (ZY), Bioqual (BIOQ), Auxly Cannabis Group (CBWTF), ProMIS Neurosciences (ARFXF), AIkido Pharma (AIKI), Inhibitor Therapeutics (INTI) and HedgePath Pharmaceuticals (HPPI). View all of MXCT's competitors. When did MaxCyte IPO? (MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share. What is MaxCyte's stock symbol? MaxCyte trades on the NASDAQ under the ticker symbol "MXCT." Who are MaxCyte's major shareholders? MaxCyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.36%), Vitruvian Partners LLP (4.32%), Vanguard Group Inc. (3.23%), River & Mercantile Asset Management LLP (2.07%), Massachusetts Financial Services Co. MA (1.84%) and American Century Companies Inc. (1.63%). Which institutional investors are selling MaxCyte stock? MXCT stock was sold by a variety of institutional investors in the last quarter, including Montanaro Asset Management Ltd, River & Mercantile Asset Management LLP, Nicholas Investment Partners LP, RTW Investments LP, Royce & Associates LP, Apis Capital Advisors LLC, TD Asset Management Inc., and Bank of New York Mellon Corp. Which institutional investors are buying MaxCyte stock? MXCT stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Vitruvian Partners LLP, Goldman Sachs Group Inc., Grandeur Peak Global Advisors LLC, State Street Corp, BlackRock Inc., Vanguard Group Inc., and First Light Asset Management LLC. How do I buy shares of MaxCyte? Shares of MXCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MaxCyte's stock price today? One share of MXCT stock can currently be purchased for approximately $4.83. How much money does MaxCyte make? MaxCyte (NASDAQ:MXCT) has a market capitalization of $490.44 million and generates $33.89 million in revenue each year. The company earns $-19.08 million in net income (profit) each year or ($0.170010) on an earnings per share basis. How many employees does MaxCyte have? MaxCyte employs 84 workers across the globe. How can I contact MaxCyte? MaxCyte's mailing address is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. The official website for MaxCyte is maxcyte.com. The company can be reached via phone at 301 944 1700, via email at [email protected], or via fax at 301-944-1703. This page (NASDAQ:MXCT) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here